Genedata Bioprocess allows us to keep track of our process development workflows and increases throughput to ensure that we develop efficient and scalable manufacturing processes for our proprietary drugs. Walter Ferlin, Ph.D., CSO at Light Chain Bioscience

BASEL, Switzerland (PRWEB)
June 27, 2023

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Light Chain Bioscience, a brand of Novimmune, has chosen the Genedata Bioprocess® enterprise platform to streamline and automate cell line and early bioprocess development of their lead candidates.

“With our pipeline of bispecific and multi-specific drug candidates rapidly growing, we needed a workflow management system that also captures all the data generated by our CDMOs and integrates them with our in-house experimental results. Genedata Bioprocess allows us to keep track of our process development workflows and increases throughput to ensure that we develop efficient and scalable manufacturing processes for our proprietary drugs,” said Walter Ferlin, Ph.D., CSO. “Being able to integrate the system with Genedata Biologics®, our existing biologics discovery workflow platform, also gives us company-wide access to both research and development data in one shared platform, which is so valuable because we can trace everything — all the way back from manufacturing through development to initial candidate selection,” said Nicolas Fischer, Ph.D., CEO at Light Chain Bioscience.

Light Chain Bioscience focuses on the development of innovative therapies using their proprietary technologies to discover and develop bispecific and multi-specific therapeutic antibodies that fully retain the native sequence and structure of human antibodies. Genedata Bioprocess is fully integrated with Genedata Biologics and supports the entire end-to-end development process at Light Chain Bioscience across CLD, USP, DSP, and analytics operations.

Co-developed over the last ten years with major biopharmaceutical companies, Genedata Bioprocess has been adopted by multinational biopharmaceuticals as well as innovative biotech companies, especially in the RNA and cell & gene therapy space. The platform integrates all data generated along the biotherapeutics development and CMC process, including cell line development, upstream, downstream, and analytics functions. It enables fully automated processes, such as streamlining highly parallelized scale-down expression experiments with mini-bioreactors. In addition, by providing an integrated platform across research and development, it accelerates and improves the drug candidate transition from research to development. Built on a modular and scalable architecture, the system is suitable for installations ranging from single-site groups to global, multi-site biopharma development organizations.

“We are delighted to see Light Chain Bioscience expanding their usage of the Genedata Biopharma Platform to now integrate both their discovery and development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We have identified the R2D transition as one of the main bottlenecks in the biopharma industry. We are pleased to see that our integrated R&D workflow platform helps our customers to overcome this challenge by reducing process complexity, automating operations, streamlining data exchange with CDMOs, and ultimately, increasing efficiency.”

About Light Chain Bioscience

Light Chain Bioscience is a clinical-stage company focused on the discovery and development of therapies based on bispecific and multi-specific antibody formats. Its proprietary κλ body platform allows for the identification of bispecific antibodies that fully retain the native sequence and structure of human antibodies. This unique property is of interest for long term treatment of patients. In immuno-oncology, Light Chain Bioscience focuses on the selective targeting of the checkpoint CD47 as well as T cell and activation redirecting strategies.

http://www.lightchainbio.com

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn | Twitter | YouTube

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:

Providing humanitarian aid is a key part of Prem Rawat’s vision for TPRF, which he founded in 2001 to help people live in dignity, peace and prosperity by addressing fundamental human needs.

“We cannot fully express our gratitude to The Prem Rawat Foundation for your support and care. We are so excited that now we can grow our daily reach thanks to your support, providing the children with more nutritious meals and a safe place.” – Leanne Lorrance, Likhon iThemba Director

LOS ANGELES (PRWEB)
June 27, 2023

A partnership between The Prem Rawat Foundation (TPRF) and Likhon iThemba, a local nonprofit that means “there is hope” in the Zulu language, began last year in the wake of torrential floods that devastated disadvantaged communities in Durban, South Africa.

To help people recover, TPRF distributed $48,000 in grants to five local organizations, including Likhon iThemba, to provide food, water and shelter. The initial aid was greatly appreciated but the floods aggravated ongoing local challenges. A new TPRF grant of $8,000 will help Likhon iThemba expand the Gogo Kitchen project, feeding children who often suffer from malnutrition and HIV.

“Gogo” means “grandmother” in Zulu and the kitchens are staffed by beloved local elders. The modest new TPRF grant will go a long way, enabling the Gogo program to serve 120 children nutritious meals five to seven days a week, doubling the current amount of three meals per week that they are able to provide. Likhon iThemba also provides a safe place for children after school where they can do homework, stay off the streets and receive adult mentorship.

The three Gogo Kitchens serve disadvantaged neighborhoods which have some of the highest rates of HIV in the world. Many children take HIV medication and if the medication is taken on an empty stomach, they get sick. At the kitchens, the children are able to take their medication on a full stomach after their meals. Likhon iThemba also runs homes for abandoned infants and disabled children.

“We cannot fully express our gratitude to The Prem Rawat Foundation for your support and care for our program. We at Likhon iThemba are continually inspired by the dedication and generosity of donors like yourself who answer the call to give again and again. We are so excited that now we can grow our daily reach thanks to your support, providing the children with more nutritious meals and a safe place,” says Leanne Lorrance, Likhon iThemba Director.

“I am personally touched by this Gogo program and I’m struck by how similar it is to the Food for People program,” says Marcia Leitner, TPRF Executive Director. “Thank you to all of the TPRF donors who make meaningful work like this possible. You are touching hearts and changing lives.”

Food for People is a signature TPRF program that has similarly helped empower people in critical need by providing over 5.2 million meals and crisis relief in India, Nepal and Ghana.

Providing humanitarian aid is a key part of Prem Rawat’s vision for TPRF, which he founded in 2001 to help people live in dignity, peace and prosperity by addressing fundamental human needs.

Last year he met with Durban officials to determine how to best help flood victims and discuss his approach to helping each other through hard times. “The Prem Rawat Foundation prides itself on getting the help to those people who truly need it,” said Mr. Rawat.

Prem Rawat recently completed a tour of South Africa to help address people’s fundamental need for peace. At events throughout the country he highlighted the Peace Education Program, providing practical guidance on how to experience personal peace by looking within and getting in touch with your heart.

Prem Rawat’s Peace Education Program, administered by TPRF, is growing in popularity across South Africa and the world by giving participants the opportunity to focus and reflect on their own humanity and their inner resources such as choice, hope and dignity. Over 300,000 people in more than 80 countries have participated in the program, including over 26,000 people in South Africa. Many report profound benefits such as enhanced self-awareness, tolerance and contentment.

Share article on social media or email:

This case series further supports the effectiveness of a whole-food, plant-predominant eating pattern as a primary intervention to achieve remission.

ST. LOUIS, Mo. (PRWEB)
June 27, 2023

A lifestyle-based treatment intervention promoting adherence to a whole-food, plant-predominant eating pattern and integrated into routine care can successfully achieve type 2 diabetes remission, according to a research study published in the American Journal of Lifestyle Medicine.

The case series determined that a sample of 59 patients from a cardiac wellness program, who also had type 2 diabetes, achieved significant improvements in blood glucose control, and in 37 percent of cases, full remission of their diabetes. The patients were treated with a low-fat, whole-food, plant-predominant dietary pattern while also receiving standard medical treatment at a wellness center in Virginia. Improvements in glucose control were accompanied by significant reductions in BMI.

Previous studies have demonstrated that whole-food, plant-predominant eating patterns can improve diabetes outcomes but that research primarily involved substantial calorie restriction, often relying on liquid meal replacements, or fasting. This study, published in collaboration with the American College of Lifestyle Medicine (ACLM), is unique in its assessment of remission as a primary outcome and contributes novel information on the feasibility of achieving remission simply by eating healthy food.

“The prevalence of diabetes is growing, as is recognition in the health care community that diet as the primary intervention can achieve lasting remission in individuals with type 2 diabetes,” said Gunadhar Panigrahi, MD, FACC, DipABLM, the first author of the study. “This case series further supports the effectiveness of a whole-food, plant-predominant eating pattern as a primary intervention to achieve remission as well as the need for increased education for both clinicians and patients on the successful application of lifestyle medicine principles and dietary interventions in everyday medical practice.”

Researchers reviewed electronic health records of patients treated at the wellness clinic between 2007 and 2021 to identify those who adopted a whole-food, plant-predominant eating pattern and achieved meaningful improvements in HbA1c or blood glucose control, as well as remission of type 2 diabetes. Data points were extracted from the periods immediately before the lifestyle intervention and the most recent post intervention.

The study used the 2022 consensus definition of remission published by ACLM of HbA1c less than 6.5% for at least three months without surgery, devices, or active pharmacologic therapy to lower blood glucose. That expert consensus statement was endorsed by the American Association of Clinical Endocrinology, supported by the Academy of Nutrition and Dietetics and co-sponsored by the Endocrine Society.

The mean age of the patients was 71.5 years and ranged in age from 41 to 89 years. Twenty-two of the 59 patients met the criteria for type 2 diabetes remission. The study also reported an average de-escalation of glucose-lowering medications among patients following lifestyle change. The reduction in glucose-lowering medications was consistent with that mentioned in a recent qualitative case series that provided the first published examples of protocols to help guide clinical decision making on when and how to deprescribe medications following lifestyle intervention. Medication deprescribing is a process that is supervised by a physician when a medication is no longer benefiting a patient.

The study highlighted that many patients did not first self-select into a lifestyle medicine treatment program for type 2 diabetes, but were rather educated on the merits of a whole-food, plant-predominant dietary pattern and regular physical activity as part of their routine care at the wellness center.

“There is a perception that many patients may not accept the idea of adopting a whole-food, plant predominant eating pattern but there is a growing abundance of research that in fact shows adherence to a plant-predominant dietary pattern is feasible, and even enjoyable,” said Micaela Karlsen, ACLM Senior Director of Research. “Although full remission may not be possible for every patient, our research shows that every patient deserves to know that it may be possible through the adopting of appropriately dosed therapeutic lifestyle change.”

Future research should measure the proportion of patients in typical medical practices who are willing to consider lifestyle changes as part of routine treatment and examine the factors leading to successful implementation of a plant-predominant dietary intervention, the authors said.

ABOUT ACLM

The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

Share article on social media or email:

WellnessEvidence.com is a ‘spin-free’ research zone where you can research studies for CBD, whether positive or negative. Because more knowledge always means more empowerment

MIAMI (PRWEB)
June 27, 2023

The nonprofit Global Wellness Institute™ (GWI), the leading research and educational resource for the global wellness industry, reminds wellness seekers that there is evidence-based medical research available on most mainstream wellness modalities – whether that evidence is good, bad or inconclusive.

“WellnessEvidence.com provides direct access to the universe of clinical studies for common wellness modalities–at the databases that doctors use–to help consumers, medical professionals, the wellness industry, and the media dive into the actual evidence (or lack thereof) for that approach,” said Susie Ellis, chair and CEO of the GWI.

“CBD, a non-psychoactive part of the cannabis sativa plant, has recently soared in popularity and has seen a lot of marketing hype as a cure-all. While studies are increasing, unlike the overwhelmingly positive evidence for approaches such as exercise or healthy sleep, the evidence around CBD can be complex and confusing,” continued Ellis. “There are too many small trials with conflicting results as well as trials and metareviews that too often include THC/CBD compounds rather than studying just pure CBD.

WellnessEvidence.com is a ‘spin-free’ research zone where you can research studies for CBD, whether positive or negative. Because more knowledge always means more empowerment.”

WellnessEvidence.com provides free and easy access to the studies on wellness approaches at the world’s most authoritative sources of evidence-based medicine, including the Cochrane Library, PubMed and the TRIP Database–in just a click or two you can explore dozens, sometimes hundreds or thousands, of studies. The site also provides summaries of representative studies, as well as the current clinical trials underway for that wellness approach.

The new platform for CBD lets people research some key questions:

• 
  Does CBD improve sleep? A small, randomized, double-blind, placebo-controlled 2022 study from Australian researchers tested medicinal cannabis oil containing THC and CBD and found that it improved sleep quality and quantity, increasing levels of the sleep hormone melatonin by 30%; while a larger 2023 study from UCLA and Scripps Clinic Sleep Center found that low doses of CBD improved sleep quality in patients with a history of sleep disturbances.
• Does CBD help with pain relief? A large 2017 report concluded that substantial evidence exists for cannabis plus cannabinoid treatment for three conditions: chronic pain, chemotherapy-induced vomiting and muscle spasms; however CBD alone may not be as effective in pain treatment, with a separate 2022 study finding that 28 days of CBD oil application did not reduce symptoms of distress and pain for patients with advanced cancer.
• Can CBD help with anxiety and other mental health conditions? A 2019 metareview indicates that there is a promising, yet unproven, role for CBD in managing anxiety disorders; while a much larger 2019 metareview published in The Lancet looked at ways CBD impacts a number of mental health conditions – including depression, anxiety, ADHD, Tourette syndrome, PTSD and psychosis – finding “scarce evidence.”

Other recent additions to WellnessEvidence.com include psilocybin, halotherapy and complementary and alternative medicine (CAM) for cancer. To access the medical evidence for the 33 featured wellness approaches, visit http://www.wellnessevidence.com.

About the Global Wellness Institute: The Global Wellness Institute (GWI), a nonprofit 501(c)(3), is considered the leading global research and educational resource for the global wellness industry and is known for introducing major industry initiatives and regional events that bring together leaders to chart the future. GWI positively impacts global health and wellness by educating public institutions, businesses and individuals on how they can work to prevent disease, reduce stress, and enhance the overall quality of life. Its mission is to empower wellness worldwide.

Share article on social media or email:

Week in RARE events

“We are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease diagnosis.” – Charlene Son Rigby, CEO of Global Genes

ALISO VEIJO, Calif. (PRWEB)
June 27, 2023

Members of the rare disease community from around the world will gather in San Diego in September for Global Genes’ Week in RARE, a set of events for patient advocates to network, learn, and inspire each other.

Week in RARE includes the RARE Health Equity Forum, the RARE Advocacy Summit, the RARE Champions of Hope Awards, and meetings for Global Genes’ Global Advocacy Alliance and its RARE Corporate Alliance. The events will run successively September 18 through 21 at the Sheraton San Diego Hotel & Marina on Harbor Island Drive in San Diego.

“By bringing these events together in a single time and place, we are creating an unparalleled opportunity for rare disease advocates to engage with each other, build relationships, and help them understand what they can do to change what it means to live with a rare disease diagnosis,” said Charlene Son Rigby, CEO of Global Genes. “In addition, these events will help patients navigate the complicated landscape of healthcare more effectively, offer patient organizations solutions to expand their reach and improve their value, and allow the entire rare disease community to understand the power they have to accelerate the development of treatments and therapies.”

The RARE Health Equity Forum (formerly known as the RARE Health Equity Summit), which runs September 18 and 19, brings together rare disease stakeholders to identify ways to better serve marginalized populations. The sessions will provide attendees with actionable tools and strategic insights to support underserved and underrepresented patients within their communities.

The RARE Advocacy Summit (formerly known as the RARE Patient Advocacy Summit), one of the world’s largest gatherings for the rare disease community, runs September 19 through 21. It provides attendees with insights about the latest rare disease innovations, best practices for advocating, and actionable strategies they can use to implement and use immediately in the areas of Personal Support and Advocacy, Community Building and Sustainability, Research and Research Enablement, Collaborations in research and insights into Science innovations.

The RARE Champions of Hope Awards will be held during the RARE Advocacy Summit on September 20. The awards recognize members of the rare disease community for their innovative approaches to research, programming, and advocacy to create meaningful impact in the rare disease space.

The content and experience for attendees at both RARE Advocacy Summit and RARE Health Equity Forum will benefit rare disease patients, caregivers, patient advocacy group leaders, rare disease advocates, researchers and biopharma working in advocacy, research and contemplating how to better support patient community partners, but all are welcome.

“We hope that more attendees can take advantage of the unique content available during both events at the Week in RARE, and see the value that each event offers,” said Nicole Boice, Founder and Chief Mission Officer of Global Genes. “In addition to plenary and keynote sessions, attendees will benefit from focused tracks, working group sessions, and our new one-to-one format providing advocates time to consult with experts about a variety of topics. We want attendees to walk away with real actionable next steps that will drive progress for themselves and their communities.”

Content partners for Week in RARE include Rosamund Stone Zander Translational Neuroscience Center at Boston Children’s Hospital, Everylife Foundation, Rare Disease Diversity Coalition (RDDC), and Undiagnosed Diseases Network Foundation. A special thank you to sponsors for RARE Health Equity Forum: Champion sponsor, Travere, and Title sponsors, Genentech and Horizon and presenting sponsors for RARE Advocacy Summit: Horizon and Travere.

About Global Genes

Global Genes is a 501(c)(3) nonprofit rare disease patient advocacy organization dedicated to providing patients and advocates with a continuum of services to accelerate their path from early support and awareness through research readiness. Using a collaborative approach that involves biopharma, researchers and advocates with data as a central core, Global Genes also enables research and data collection through the RARE-X research program. Through this effort, Global Genes is building the largest collaborative patient-driven, open-data access initiative for rare diseases globally.

Share article on social media or email:

MCG Health, Regence Health Plans, and MultiCare Connected Care, were recognized by KLAS with the 2023 Points of Light award.

“MCG is humbled to stand with Regence and MultiCare Connected Care as recipients of the 2023 KLAS Points of Light award. This collaboration sets the stage for a new era in patient-centered care with evidence-based clinical decisions and timelier treatment.” – Jon Shreve, MCG President & CEO

SEATTLE, Wash. (PRWEB)
June 27, 2023

MCG Health, part of the Hearst Health network and an industry leader in technology-enabled, evidence-based guidance, along with Regence Health Plans and MultiCare Connected Care, were recognized by KLAS with the 2023 Points of Light award. This was the first collaboration between a payer, provider, and clinical decision support vendor to produce a scalable and automated prior authorization (PA) workflow based on the HL7 Da Vinci Project’s implementation guides (IGs). The three organizations were presented with the KLAS Points of Light award during the annual KLAS K2 Summit on May 10, 2023, in Salt Lake City.

KLAS recognized MCG, Regence, and MultiCare Connected Care for utilizing interoperability standards from the HL7 Da Vinci Project to create an end-to-end HL7 FHIR® (Fast Healthcare Interoperability Resources) workflow for prior authorizations. This technology automated the submission of prior authorization requests from the provider’s electronic health record (EHR) to the payer’s medical management system and was able to return an authorization determination in real-time back to the provider’s EHR. MCG’s rules engine was integrated into the process to ensure care decisions were support by vetted, scientific evidence.

The results recognized as part of the award include:

• 
  60% of auth requests were able to be completed immediately as “no auth required” and communicated to the provider via their EHR
• 41% of requests requiring prior auth (from an initial data sample) were auto approved which meant no human review was required
• The provider achieved 140% to 230% increase in PA productivity
• Improved workflows for the payer and provider, leading to faster authorization decisions; Many determinations were returned in seconds, compared to a previous turnaround time of three-to-five days
• Reduced administrative burden for stakeholders, and faster access to care for patients

MCG President and CEO, Jon Shreve, said of the recognition, “MCG is humbled to stand with Regence and MultiCare Connected Care as recipients of the 2023 KLAS Points of Light award. This collaboration sets the stage for a new era in patient-centered care with evidence-based clinical decisions and timelier treatment.”

KLAS’ annual Points of Light awards celebrate success stories—or “points of light”—achieved by payers, healthcare organizations, and vendors who have partnered to reduce costs and inefficiencies and improve the patient experience. In total, 25 collaborations were awarded a 2023 Points of Light award. The report is available to KLAS members here: https://klasresearch.com/report/points-of-light-2023-case-study-14-leveraging-hl7-fhir-interoperability-standards-to-automate-prior-authorizations/3183

###

About Regence

Regence serves more than 3.4 million people through its Regence health plans in Idaho, Oregon, Utah and Washington. Each Regence health plan is a nonprofit independent licensee of the Blue Cross and Blue Shield Association. Regence is part of a family of companies dedicated to transforming health care by delivering innovative products and services that change the way consumers nationwide experience health care. For more information, please visit regence.com.

About MultiCare Connected Care

MultiCare Connected Care (MCC) is an independent Accountable Care Organization (ACO) established in 2014 as a wholly owned subsidiary of MultiCare Health System and operates as an independent entity. It is transforming healthcare as a population health engine that represents a Clinically Integrated network (CIN) of independent & MultiCare Health System clinicians’ services across the entire social medical model of care. Under this entity, 350,000 lives are served within 30 value-based contracts.

Unlike the traditional “fee for service” health care model – where each visit, service, test, and procedure has a separate cost – MCC‘s foundation is built first and foremost on providing patient-centered, quality care at an appropriate cost. Specific measures are used to determine how well doctors, hospitals, and other providers are keeping healthy people healthy, effectively treating illnesses, and helping people better manage their chronic conditions. In this way, all the participating providers share the responsibility of providing patient-centered, high quality, efficient, cost-effective care.

MCC has established a comprehensive Clinically Integrated Network (CIN) comprised of doctors and other health care providers, as well as hospitals, clinics, and other health care services, such as imaging, labs, and pharmacies. The CIN includes independent health care professionals in the community, as well as MultiCare-employed providers, totaling over 5,100 clinicians providing services across the continuum of care. multicareconnectedcare.com

About MCG Health

MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG’s artificial intelligence and technology, infused with clinical expertise, enable its clients to prioritize and simplify their work. MCG’s world-class customer service ensures that clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes.

For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

About Hearst Health

The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Care guidance from Hearst Health reaches the majority of people in the U.S. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.

Share article on social media or email: